Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4367652 | PMC |
| http://dx.doi.org/10.3978/j.issn.2218-6751.2012.11.03 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
[Not Available].
Bull Cancer
October 2024
Service d'oncologie endocrinienne, Département d'imagerie, Gustave-Roussy, F-94805 Villejuif, France.
MANAGING MEDULLARY THYROID CARCINOMA IN 2024: Medullary thyroid carcinoma is a rare neuroendocrine thyroid cancer with a heterogeneous prognosis which has the particularity of being associated with a RET gene mutation, germline in 20-25% of cases in the context of multiple endocrine neoplasia type 2 (NEM2), and somatic in 70% of sporadic cases. It is often diagnosed on a thyroid nodule or in the context of genetic screening. Calcitonin is a biological marker, used for diagnosis, monitoring of therapeutic response and prognostic evaluation.
View Article and Find Full Text PDFTailored management of advanced thyroid cancer patients treated with lenvatinib or vandetanib: the role of a multimodal approach.
Endocrine
October 2024
Oncological Endocrinology Unit, Department of Medical Sciences, Città Della Salute e Della Scienza Hospital, University of Turin, Turin, Italy.
Background: In differentiated/poorly differentiated (DTC/PDTC) or medullary thyroid cancer (MTC) treated with kinase inhibitors (KIs), additional treatments (ATs) can be performed in selected cases.
Methods: We retrospectively analysed all the ATs performed in our center in KI-treated TC patients, evaluating the subsequent KI modulation, the local PD in case of loco-regional procedure (LRP) and the AT-related complications. DTC/PDTC patients with or without progressive disease before the first AT (PD and NO PD GROUP, respectively) were analysed separately.
Molecular genetics, therapeutics and RET inhibitor resistance for medullary thyroid carcinoma and future perspectives.
Cell Commun Signal
September 2024
Department of Thyroid Surgery, Zhejiang Cancer Hospital, No. 1 East Banshan Road, Gongshu District, Hangzhou, 310022, Zhejiang, China.
Article Synopsis
- * Standard treatment for early-stage MTC is surgery, with a 10-year survival rate over 80%, while metastatic cases face lower survival rates (10-40%) and limited effective therapies.
- * Recent advancements in targeted therapies, particularly RET inhibitors like Cabozantinib, Vandetanib, Selpercatinib, and Pralsetinib, offer new hope, though challenges such as drug resistance and side effects still complicate treatment for advanced MTC.
Efficacy and Safety of Multikinase Inhibitors for Patients With Refractory Thyroid Cancer: Systematic Review and Network Meta-Analysis.
J Clin Endocrinol Metab
September 2024
Department of Breast and Thyroid Surgery, South China Hospital of Shenzhen University, Shenzhen 518111, China.
Context: Multikinase inhibitors (MKIs) improve the treatment of refractory thyroid cancer, including radioactive iodine-refractory differentiated thyroid cancer (RAIR-DTC) and advanced medullary thyroid carcinoma (aMTC).
Objective: This study aims to compare the efficacy of MKIs in improving survival outcomes and safety.
Data Sources: Comprehensive database searches of MEDLINE via PubMed, EMBASE, and Cochrane were performed from inception to December 2023.
Vandetanib in locally advanced or metastatic differentiated thyroid cancer refractory to radioiodine therapy.
Endocr Relat Cancer
August 2024
Department of Nuclear Medicine and Endocrine Oncology, Gustave Roussy and Université Paris Saclay, Villejuif, France.
Article Synopsis
- The VERIFY study investigated the effectiveness of vandetanib in patients with advanced differentiated thyroid cancer that did not respond to radioiodine therapy, focusing on its safety and efficacy compared to a placebo in a randomized, double-blind phase III trial.
- The trial involved 235 patients, divided equally to receive either vandetanib or a placebo, with the main goal of assessing progression-free survival (PFS), which was found to be 10.0 months for the vandetanib group versus 5.7 months for the placebo group.
- Despite showing a longer PFS, the study did not find a significant overall survival (OS) benefit, and patients receiving vandetanib experienced more severe adverse events and deaths compared to those
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!